# ISLET CELL AUTOANTIBODIES AND NATURAL HISTORY OF IDDM

> **NIH NIH R01** · UNIVERSITY OF FLORIDA · 1994 · $553,070

## Abstract

This is a study of the natural history of pathogenic events leading to the
clinical onset of insulin dependent diabetes (IDD).  The goals are to gain
insights into the disease process so as to be able to predict who will
develop the disease and when.  The three study populations are:  high risk
relatives of IDD probands, intermediate risk patients with autoimmune
thyroid and/or adrenal diseases and their families, and low risk general
population of school children.  The three University Medical Centers in
Florida as well as 5 satellite groups will participate.  Current predictive
markers include islet cell (cytoplasmic) autoantibodies (ICA), insulin
autoantibodies (IAA), elevations of fasting plasma glucose (more than
110mg/ml) and impaired early phase insulin release to IVGTT, with risks
determined by life table analyses of data obtained from single
observations.  We now intend to estimate risks from sequential data
obtained through multiple observations and the recursive partitioning of
risk groups, and to add several new potential immunologic and metabolic
markers.  Autoantibodies to an islet cell protein of 64KDa (64KA) may be
the best early predictive marker.  The 64KDa antigen has been shown
recently to be the 65KDa variant of glutamic acid decarboxylase (GAD).
This antibody will be identified by an immunoassay utilizing recombinant
GAD proteins.  Autoantibodies to insulin receptors and lymphocyte antigens
will also be sought.  Defects in cellular mediated immunity have also been
identified in relatives with impending IDD.  These defects include relative
lymphopenia, increased circulating T cells bearing gamma-delta T cell
receptors, decreased T cell helper-inducer function and persistence of
infant frequencies of circulating CD5+ B cells into adulthood.  Metabolic
parameters to be explored include possible hyperglucagonemia and insulin
resistance measures made through infusions of stable label glucose and
minimal modelling analyses.  These continued studies will provide an
increasingly accurate basis for predicting the risk of IDD, a necessity in
the development of intervention strategies to prevent IDD.

## Key facts

- **NIH application ID:** 2197819
- **Project number:** 5R01HD019469-11
- **Recipient organization:** UNIVERSITY OF FLORIDA
- **SAM.gov UEI:** NNFQH1JAPEP3
- **Principal Investigator:** NOEL K MACLAREN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1994
- **Award amount:** $553,070
- **Award type:** 5
- **Project period:** 1984-05-01 → 1997-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/2197819

## Citation

> US National Institutes of Health, RePORTER application 2197819, ISLET CELL AUTOANTIBODIES AND NATURAL HISTORY OF IDDM (5R01HD019469-11). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/2197819. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*